---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-001890"
form_type: "8-K"
ticker: "BYSI"
cik: "0001677940"
company_name: "BeyondSpring Inc."
filed_at: "2026-03-25T23:59:59+00:00"
generated_at: "2026-05-15T09:01:55.010362+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# BeyondSpring reports FY2025 net loss $8.7M; Plinabulin Phase 3 survival benefit confirmed, DUBLIN-4 planned

## Summary
- R&D expense $4.4M, G&A $4.6M; cash $12.6M as of Dec 31, 2025.
- Plinabulin+docetaxel achieved OS HR 0.72 in non-squamous NSCLC; DUBLIN-4 confirmatory trial planned.
- SEED Therapeutics dosed first patient in Phase 1a for ST-01156; completed $30M Series A-3 financing.
- Sold portion of SEED preferred shares for ~$35.4M gross proceeds; first closing $7.35M in Feb 2025.

## SEC filing metadata
- accession: 0001171843-26-001890
- form_type: 8-K
- ticker: BYSI
- cik: 0001677940
- company_name: BeyondSpring Inc.
- filed_at: 2026-03-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1677940/000117184326001890/0001171843-26-001890-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1677940/000117184326001890/f8k_032526.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-001890
- JSON: https://secwatch.observer/filing/0001171843-26-001890.json
- Plain text: https://secwatch.observer/filing/0001171843-26-001890.txt

## Key facts
- Earnings Releases
  BeyondSpring Inc. reported financial results for the full year ended December 31, 2025.
  - Period: the full year ended December 31, 2025
  - Result: reported results
  source text: On March 25, 2026, BeyondSpring Inc. (the “Company”) issued a press release announcing its financial results for the full year ended December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1677940/000117184326001890/0001171843-26-001890-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.